We are live on ! Find out more
ZVSA

ZyVersa Therapeutics
ZVSA

Delisted

ZVSA was delisted on the 16th of July, 2025.

Back to rankings

7 hedge funds and large institutions have $43.9K invested in ZyVersa Therapeutics in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.51% less ownership

Funds ownership: 3.23% → 2.72% (-0.51%)

13% less funds holding

Funds holding: 8 → 7 (-1)

49% less capital invested

Capital invested by funds: $86.2K → $43.9K (-$42.3K)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
7
Holders Change
-1
Holders Change %
-12.5%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$27.2K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$24.5K
3
Bank of America
Bank of America
North Carolina
+$2

Top Sellers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
-$37.1K
2
Renaissance Technologies
Renaissance Technologies
New York
-$13.7K
3
VF
Virtu Financial
New York
-$8.72K
4
TRCT
Tower Research Capital (TRC)
New York
-$1.5K

ZVSA Hedge Fund Activity: Q1 2025 in Review

7 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics (ZVSA) for Q1 2025, worth a combined $43.9K — down 49% from $86.2K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of ZVSA and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.

The largest buyer was UBS Group, adding an estimated $27.2K. The largest seller was Citigroup, exiting entirely with an estimated $37.1K sold.

  • 7 institutional investors held ZyVersa Therapeutics (ZVSA) as of Q1 2025, down from 8 in Q4 2024.
  • Funds reported $43.9K of ZyVersa Therapeutics stock for Q1 2025, down 49% quarter-over-quarter.
  • 1 fund opened new ZyVersa Therapeutics positions in Q1 2025 and 2 closed out, a net change of -1 holder.
  • The largest ZyVersa Therapeutics buyer in Q1 2025 was UBS Group, an estimated $27.2K added.
  • The largest ZyVersa Therapeutics seller in Q1 2025 was Citigroup, an estimated $37.1K sold.

Based on aggregated 13F filings for Q1 2025.